Zhejiang Hisun Pharmaceutical (600267.SH) releases a forecasted profit, estimating a net profit of 570-630 million yuan in 2024, turning losses into profits.
Guangzhou Pharmaceuticals Corporation (stock code: 600267.SH) announced that the company is expected to achieve attributable net profit to shareholders of the listed company for the year 2024...
Zhejiang Hisun Pharmaceutical (600267.SH) announced that the company expects to achieve a net profit attributable to shareholders of the listed company of 570 million to 630 million yuan in 2024, compared to a loss in the same period last year.
Related Articles
Wu Hongsheng reduces holdings in I-CABLE COMM (01097) by 16.48 million shares, with a price of approximately HK$0.13 per share.
Conch International Holdings (HK) Limited reduced its holdings of Huaxin Cement (06655) by approximately 8.38 million shares, with a price per share of around 17.31 Hong Kong dollars.
Beijing Tieke Shougang Railway-Tech (688569.SH) won a total of 654 million yuan in bidding for engineering projects.
Wu Hongsheng reduces holdings in I-CABLE COMM (01097) by 16.48 million shares, with a price of approximately HK$0.13 per share.
Conch International Holdings (HK) Limited reduced its holdings of Huaxin Cement (06655) by approximately 8.38 million shares, with a price per share of around 17.31 Hong Kong dollars.
Beijing Tieke Shougang Railway-Tech (688569.SH) won a total of 654 million yuan in bidding for engineering projects.
RECOMMEND
